HEMATOLOGICAL MALIGNANCIES - REVIEW ARTICLE |
[View FULLTEXT] [Download PDF] |
|
| Year : 2011 | Volume
: 48
| Issue : 4 | Page : 438--445 |
Nilotinib as first-line therapy for chronic myeloid leukemia
A Vaid
Department of Medical Oncology, Cancer Institute, Medanta Hospital, Medicity, Sector 38, Gurgaon, NCR, Delhi, India
Correspondence Address:
A Vaid
Department of Medical Oncology, Cancer Institute, Medanta Hospital, Medicity, Sector 38, Gurgaon, NCR, Delhi
India
Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.
How to cite this article:
Vaid A. Nilotinib as first-line therapy for chronic myeloid leukemia.Indian J Cancer 2011;48:438-445
|
How to cite this URL:
Vaid A. Nilotinib as first-line therapy for chronic myeloid leukemia. Indian J Cancer [serial online] 2011 [cited 2022 Aug 19 ];48:438-445
Available from: https://www.indianjcancer.com/article.asp?issn=0019-509X;year=2011;volume=48;issue=4;spage=438;epage=445;aulast=Vaid;type=0 |
|
